secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2021-07-26T23:59:59+00:00
Accession:  0001193125-21-223659
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis closes exchange of $201.1M convertible notes for 5.99M common shares
----------------------------------------------------------------------------

- Exchanged $201.1M principal of 3.500% Convertible Senior Notes due 2026 for 5,992,217 common shares.
- After exchange, approximately $192.7M principal amount of Notes remain outstanding with third parties.
- Transaction closed on July 23, 2021; shares issued are unregistered and restricted.
- Privately negotiated exchange reduces debt and dilutes existing equity by ~3% based on prior share count.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312521223659/0001193125-21-223659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312521223659/d217083d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-223659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer